Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)

Journal of Steroid Biochemistry and Molecular Biology

Volumn 153, Issue , 2015, Pages 105-113

  Penning, Trevor M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Androgen receptor; Prostate cancer; Steroidogenesis; Therapeutics

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ENZALUTAMIDE; GALETERONE; GTX 560; INDOMETACIN; IROSUSTAT; LEUPRORELIN; PREDNISONE; STEROID 17ALPHA MONOOXYGENASE; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

ANDROGEN SYNTHESIS; ARTICLE; BIOAVAILABILITY; CASTRATION RESISTANT PROSTATE CANCER; DRUG RESISTANCE; DRUG TARGETING; GENE AMPLIFICATION; HUMAN; HYPERTENSION; MOLECULAR MECHANICS; MUTATION; SEIZURE; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANDROSTENES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84941260680     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2015.05.010     Document Type: Article

References (79)

1. SEER, Surveilance, Epidemiology, and End Results Program. http://seer.cancer.gov/statfacts/html/prost.html, 2014.
2. R. Sharifi, R.C. Bruskewitz, M.C. Gittleman, S.D. Graham Jr., P.B. Hudson, and B. Stein Leuprolide acetate 22. 5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer Clin. Ther. 18 1996 647 657
3. K. Knudsen, and T.M. Penning Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol. Metab. 21 2010 315 324
4. J.L. Mohler, C.W. Gregory, O.H. Ford 3rd, D. Kim, C.M. Weaver, P. Petrusz, E.M. Wilson, and F.S. French The androgen axis in recurrent prostate cancer Clin. Cancer Res. 10 2004 440 448
5. C. Cai, S. Chen, P. Ng, G.J. Bubley, P.S. Nelson, E.A. Mostaghel, B. Marck, A.M. Matsumoto, N.I. Simon, H. Wang, S. Chen, and S.P. Balk Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors Cancer Res. 71 2011 6503 6513
6. M. Knuuttila, E. Yatkin, J. Kallio, S. Savolainen, T.D. Laajala, T. Aittokallio, R. Oksala, M. Häkkinen, P. Keski-Rahkonen, S. Auriola, M. Poutanen, and S. Mäkelä Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model Am. J. Pathol. 184 2014 2163 2173
7. C.G. Leon, J.A. Locke, H.H. Adomat, S.L. Etinger, A.L. Twiddy, R.D. Neumann, C.C. Nelson, E.S. Guns, and K.M. Wasan Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model Prostate 70 2010 390 400
8. J.A. Locke, E.S. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, C.A. Wood, S.L. Ettinger, M.E. Gleave, and C.C. Nelson Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res. 68 2008 6407 6415
9. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higian, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 68 2008 4447 4454
10. M.A. Fenton, T.D. Shuster, A.M. Fertig, M.E. Taplin, G. Kolvenbag, G.J. Bubley, and S.P. Balk Functional characterization of mutant androgen receptors from androgen-independent prostate cancer Clin. Cancer Res. 3 1997 1383 1388
11. T. Hara, J. Miyazaki, H. Araki, M. Yamaoka, N. Kanzaki, M. Kusaka, and M. Miyamoto Novel mutations of the androgen receptor: a possible mechanism of bicalutamide withdrawal Cancer Res. 63 2003 149 153
12. H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, E. Efstathiou, D. Rathkopf, J. Shelkey, E.Y. Yu, J. Alumkal, D. Hung, M. Hirmand, L. Seely, M.J. Morris, D.C. Danila, J. Humm, S. Larson, M. Fleisher, C.L. Sawyers, and Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
13. X.-B. Shi, A.-H. Ma, L. Xia, H.-J. Kung, and R.W. de Vere White Mutational analysis of 44 mutant androgen receptors from human prostate cancer Cancer Res. 62 2002 1496 1502
14. M.E. Taplin, G.J. Bubley, T.D. Shuster, M.E. Frantz, A.E. Spooner, G.K. Ogata, H.N. Keer, and S.P. Balk Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N. Engl. J. Med. 332 1995 1393 1398
15. M.E. Taplin, G.J. Bubley, Y.J. Ko, E.J. Small, M. Upton, B. Rajeshkumar, and S.P. Balk Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res. 59 1999 2511 2515
16. T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinänen, C. Palmberg, A. Palotie, T. Tammela, J. Isola, and O.P. Kallioniemi In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat. Genet. 9 1995 401 406
17. G. Attard, A.H.M. Reid, T.A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martinins, E. Folkerd, J. Clark, C.S. Cooper, S.B. Kaye, D. Dearnaley, G. Lee, and J.S. de Bono Phase 1 clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confrims that castration-resistant prostate cancer commonly remains hormone driven J. Clin. Oncol. 28 2008 4563 4571
18. G. Attard, A.H. Reid, R. A'Hern, C. Parker, N.B. Oommen, E. Folkerd, C. Messiou, L.R. Molife, G. Maier, E. Thompson, D. Olmos, R. Sinha, G. Lee, M. Dowsett, S.B. Kaye, D. Dearnaley, T. Kheoh, A. Molina, and J.S. de Bono Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J. Clin. Oncol. 27 2009 3742 37482
19. G. Attard, A.H. Reid, D. Olmos, and J.S. de Bono Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven Cancer Res. 69 2009 4937 4940
20. D.C. Danila, M.J. Morris, J.S. de Bono, C.J. Ryan, S.R. Denmeade, M.R. Smith, M.E. Taplin, G.J. Bubley, T. Kheoh, C. Haqq, A. Molina, A. Anand, M. Koscuiszka, S.M. Larson, L.H. Schwartz, M. Fleisher, and H.I. Scher Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J. Clin. Oncol. 28 2010 1496 1501
21. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M. Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. Welsbie, C.D. Chen, C.S. Higano, T.M. Beer, D.T. Hung, H.I. Scher, M.E. Jung, and C.L. Sawyers Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
22. T.M. Beer, A.J. Armstrong, D.E. Rathkopf, Y. Loroit, C.N. Sternberg, C.S. Higano, P. Iverson, S. Bhattacharya, J. Carles, S. Chowdury, I.D. Davis, J.S. de Bono, C.P. Evans, K. Fizazi, A.M. Joshua, C.-S. Kim, G. Kimura, P. Mainwairng, H. Mansbach, K. Miller, S.B. Nonnberg, F. Perabo, D. Phung, F. Sadd, H.I. Scher, M.-E. Taplin, P.M. Venner, and B. Tombal Enzalutamide in metastatic prostate cancer before chemotherapy for the PREVAIL Investigators N. Engl. J. Med. 371 2014 424 433
23. K. Fizazi, I. Scher, A. Malina, C.J. Logothetis, K.N. Chi, R.J. Jones, J.N. Staffurth, S. North, N.J. Vogelzang, F. Saad, P. Mainwairing, S. Harland, O.B. Goodman Jr., C.N. Sternberg, J.H. Li, T. Kehoh, C.M. Haqq, and J.S. de Bono Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study for the COU-AA-301 Investigators Lancet Oncol. 13 2012 983 992
24. C.J. Ryan, M.R. Smith, L. Fong, J.E. Rosenberg, P. Kantoff, F. Raynaus, V. Martins, G. Lee, T. Kheoh, J. Kim, A. Molina, and E.J. Small Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J. Clin. Oncol. 28 2010 1481 1488
25. C.J. Ryan, A. Molina, J. Li, T. Khoh, E.J. Small, C.M. Haqq, R.P. Grant, J.S. de Bono, and H.I. Scher Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial J. Clin. Oncol. 31 2013 2791 2798
26. M.E. Taplin, B. Montgomery, C.J. Logothetis, G.J. Bubley, J.P. Richie, B.L. Dalkin, M.G. Sanda, J.W. Davis, M. Loda, L.D. True, P. Troncoso, H. Ye, R.T. Lis, B.T. Marck, A.M. Matsumoto, S.P. Balk, E.A. Mostaghel, T.M. Penning, P.S. Nelson, W. Xie, Z. Jiang, C.M. Haqq, D. Tamae, N. Tran, W. Peng, T. Kheoh, A. Molina, and P.W. Kantoff Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study J. Clin. Oncol. 32 2014 3705 3715
27. W.R. Foster, B.D. Car, H. Shi, P.C. Levesque, M.T. Obermeier, J. Gan, J.C. Arezzo, S.S. Powlin, J.E. Dinchuk, A. Balog, M.E. Salvati, R.M. Attar, and M.M. Gottardis Drug safety is a barrier to the discovery and development of new androgen receptor antagonists Prostate 71 2011 480 488
28. N.J. Clegg, J. Wongvipat, J.D. Joseph, C. Tran, S. Ouk, A. Dilhas, Y. Chen, K. Grillot, E.D. Bischoff, L. Cai, A. Aparicio, S. Dorow, V. Arora, G. Shao, J. Qian, H. Zhao, G. Yang, C. Cao, J. Sensintaffar, T. Wasielewska, M.R. Herbert, C. Bonnefous, B. Darimont, H.I. Scher, P. Smith-Jones, M. Klang, N.D. Smith, E. De Stanchina, N. Wu, O. Ouerfelli, P.J. Rix, R.A. Heyman, M.E. Jung, C.L. Sawyers, and J.H. Hager ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res. 72 2012 1494 1503
29. H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, E. Efstathiou, D. Rathkopf, J. Shelkey, E.Y. Yu, J. Alumkal, D. Hung, M. Hirmand, L. Seely, M.J. Morris, D.C. Danila, J. Humm, S. Larson, M. Fleisher, C.L. Sawyers, and Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
30. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, P. Mulders, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, and J.S. de Bono Increased survival with enzalutamide in prostate cancer after chemotherapy AFFIRM Investigators N. Engl. J. Med. 367 2012 1187 1197
31. E. Cho, R.B. Montgomery, and E.A. Mostaghel Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression Endocrinology 155 2014 4124 4132
32. M. Yang, W. Xie, E. Mostaghel, M. Nakabayashi, L. Werner, T. Sun, M. Pomerantz, M. Freedman, R. Ross, M. Regan, N. Sharifi, W.D. Figg, S. Balk, M. Brown, M.E. Taplin, W.K. Oh, G.S. Lee, and P.W. Kantoff SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer J. Clin. Oncol. 29 2011 2565 2573
33. K.-H. Chang, R. Li, B. Kuri, Y. Lotan, C.G. Roehrborn, J. Liu, R. Vessella, P.S. Nelson, P. Kapur, X. Guo, H. Mirzaei, R.J. Auchus, and N. Sharifi A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer Cell 154 2013 1074 1084
34. H. Arakawa, T. Nakanishi, C. Yanagihara, T. Nishimoto, T. Wakayama, A. Mizokami, M. Namiki, K. Kawai, and I. Tamai Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions Biochem. Pharmacol. 84 2012 1070 1077
35. K.-M. Fung, E.H. Shea-Samara, C. Wong, R. Krin, A.M. Jones, B. Bane, C.Z. Liu, J.T. Yang, J.V. Pitha, D.J. Culkin, B.P. Koop, T.M. Penning, and H.-K. Lin Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with the androgen receptor in prostate carcinoma Endocrinol. Relat. Cancer 13 2006 169 180
36. H.-K. Lin, J.M. Jez, B.P. Schlegel, D.M. Peehl, J.A. Pachter, and T.M. Penning Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution Mol. Endocrinol. 11 1997 1971 1984
37. T.M. Penning, M.E. Burczynski, J.M. Jez, C.-F. Hung, H.-K. Lin, H. Ma, M. Moore, N. Palackal, and K. Ratnam Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochem. J. 351 2000 67 77
38. T.M. Penning, S. Steckelbroeck, D.R. Bauman, M.W. Miller, D.M. Peehl, K.-M. Fung, and H.K. Lin Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors Mol. Cell. Endocrinol. 248 2006 182 191
39. A.R. Hamid, M.J. Pfeiffer, G.W. Verhaegh, E. Schaafsma, A. Brandt, F.C. Sweep, J.P. Sedelaar, and J.A. Schalken Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer Mol. Med. 18 2012 1449 1455
40. J. Hofland, W.M. van Weerden, N.F.J. Dits, J. Steenbergen, G.J.L.H. van Leenders, G. Jenster, F.H. Schroder, and F.H. de Jomg Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer Cancer Res. 70 2010 1256 1264
41. C. Liu, W. Lou, Y. Zhu, J.C. Yang, N. Natiminty, N. Gaikwad, C.P. Evans, and A.C. Gao Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer Cancer Res. February 2015 pii: canres.3080.2014. [Epub ahead of print]
42. M.J. Pfeiffer, F.P. Smit, J.P. Sedelaar, and J.A. Schalken Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer Mol. Med. 17 2011 657 664
43. Y. Tian, L. Zhao, H. Zhang, X. Liu, L. Zhao, X. Zhao, and J. Li AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression Diagn. Pathol. 9 2014 42 48
44. N. Mitsiades, C.C. Sung, N. Schultz, D.C. Danila, B. He, V.K. Eedunuri, M. Fleisher, C. Sander, C.L. Sawyers, and H.I. Scher Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors Cancer Res. 72 2012 6142 6152
45. K. Powell, L. Semann, M.K. Conley-LaComb, I. Asangani, Y.-M. Wu, K.B. Ginsburg, J. Williams, J.A. Squire, K.R. Maddipati, M.L. Cher, and S.R. Chinni ERG/AKR 1C3/AR constitutes a feed-forward loop for AR signaling in prostate cancer cells Clin. Cancer Res. March 2015 10.1158/1078-0432.CCR-14-2352
46. M. Stanbrough, G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, P.G. Febbo, and S.P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 66 2006 2815 2825
47. E. Jernberg, E. Thysell, E.B. Ylitalo, S. Rudolfsson, S. Crnalic, A. Widmark, A. Bergh, and P. Wikstrom Characterization of the prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants PLoS One 8 2013 e77407
48. D.R. Bauman, S. Steckelbroeck, M.V. Williams, D.M. Peehl, and T.M. Penning Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α,17β-diol to 5α-dihydrotestosterone. A potential therapeutic target for androgen dependent disease Mol. Endocrinol. 20 2006 444 458
49. J.L. Mohler, M.A. Titus, S. Bai, B.J. Kennerley, F.B. Lih, K.B. Tomer, and E.M. Wilson Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer Cancer Res. 71 2011 1486 1496
50. J.L. Mohler, M.A. Titus, and E.M. Wilson Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone Clin. Cancer Res. 17 2011 5844 5849
51. F. Ishizaki, T. Nishiyama, T. Kawasaki, Y. Miyashiro, N. Hara, I. Takizawa, M. Naito, and K. Takahashi Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer Sci. Rep. 3 2013 1528 10.1038/srep01528
52. E.A. Mostaghel, B.T. Marck, S.R. Plymate, R.L. Vessella, S.P. Balk, A.M. Matsumoto, P.S. Nelson, and R.B. Montgomery Resistance to CYP17A1 inhibition with abiraterone in castrate-resistance prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin. Cancer Res. 17 2011 5913 5925
53. C.C.T. Sprenger, and S.R. Plymate The link between androgen receptor splice variants and castration-resistant prostate cancer Horm. Cancer 5 2014 207 2014
54. P.A. Watson, Y.F. Chen, M.D. Balbas, J. Wongvipat, N.D. Socci, A. Viale, K. Kim, and C.L. Sawyers Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor Proc. Natl. Acad. Sci. U. S. A. 107 2010 16759 16765
55. B. Cao, Y. Qi, G. Zhang, D. Xu, Y. Zhan, X. Alvarez, Z. Guo, X. Fu, S.R. Plymate, O. Sartor, H. Zhang, and Y. Dong Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy Oncotarget 5 2014 1646 1656
56. R. Hu, C. Lu, E.A. Mostaghel, S. Yegnasubramanian, M. Gurel, C. Tannahill, J. Edwards, W.B. Isaacs, P.S. Nelson, E. Bluemn, S.R. Plymate, and J. Luo Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer Cancer Res. 72 2012 3457 3462
57. E.S. Antonarakis, C. Lu, H. Wang, B. Luber, M. Nakazawa, J.C. Roeser, Y. Chen, T.A. Mohammad, Y. Chen, H.L. Fedor, T.L. Lotan, Q. Zheng, A.M. De Marzo, J.T. Isaacs, W.B. Isaacs, R. Nadal, C.J. Paller, S.R. Denmeade, M.A. Carducci, M.A. Eisenberger, and J. Luo AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N. Engl. J. Med. 371 2014 1028 1038
58. Z. Yu, S. Chen, A.G. Sowalsky, O.S. Voznesensky, E.A. Mostaghel, P.S. Nelson, C. Cai, and S.P. Balk Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer Clin. Cancer Res. 20 2014 1590 1600
59. M. Korpal, J.M. Korn, X. Gao, D.P. Rakiec, D.A. Ruddy, S. Doshi, J. Yuan, S.G. Kovats, S. Kim, V.G. Cooke, J.E. Monahan, F. Stegmeier, T.M. Roberts, W.R. Sellers, W. Zhou, and P. Zhu An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide) Cancer Discov. 3 2013 1030 1043
60. A.A. Azad, S.V. Volik, A.W. Wyatt, A. Haegert, S. Le Bihan, R.H. Bell, S. Anderson, B. McConeghy, R. Shukin, J. Bazov, J. Youngren, P.L. Paris, G.V. Thomas, E.J. Small, Y. Wang, M.E. Gleave, C.C. Collins, and K.N. Chi Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer Clin. Cancer Res. February 2015 pii: clincanres.2666.2014. [Epub ahead of print]
61. C. Song, Y. Kim, G.E. Min, and H. Ahn Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway Prostate 74 2014 1240 1248
62. V.K. Aora, E. Schenkein, R. Murali, S.K. Subudhi, J. Wongvipat, M.D. Balbas, N. Sah, L. Cai, E. Efstathiou, C. Logothetis, D. Zhang, and C.L. Sawyers Glucocorticoid receptor confers resistance to anti-androgens by by-passing androgen receptor blockade Cell 155 2013 1309 1322
63. N. Sharifi Steroid receptors aplenty in prostate cancer N. Engl. J. Med. 370 2014 970 971
64. O. Sartor, C.C. Parker, and J. de Bono Reappraisal of glucocorticoids in castrate-resistant prostate cancer Asian J. Androl. 16 2014
65. H.H. Cheng, R. Gulati, A. Azad, R. Nadal, P. Twardowski, U.N. Vaishampayan, N. Agarwal, E.I. Heath, S.K. Pal, H.T. Rehman, A. Leiter, J.A. Batten, R.B. Montgomery, M.D. Galsky, E.S. Antonarakis, K.N. Chi, and E.Y. Yu Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel Prostate Cancer Prostatic Dis. January 2015 10.1038/pcan.2014.53 [Epub ahead of print]
66. A. Purohit, and P.A. Foster Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers J. Endocrinol. 212 2012 99 110
67. J. Roy, J. Lefebvre, R. Maltais, and D. Poirier Inhibition of dehydroepiandosterone sulfate action in androgen-sensitive tissues by EM-1913, an inhibitor of steroid sulfatase Mol. Cell. Endocrinol. 376 2013 148 155
68. Z. Yu, C. Cai, S. Gao, N.I. Simon, H.C. Shen, and S.P. Balk Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor Clin. Cancer Res. 20 2014 4075 4085
69. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, J.D. Winkler, and T.M. Penning Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) Bioorg. Med. Chem. Lett. 21 2011 1464 1468
70. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, M. Chen, J.D. Winkler, and T.M. Penning Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships J. Med. Chem. 55 2012 2311 2323
71. M.C. Byrns, S. Steckelbroeck, and T.M. Penning An indomethacin analogue N-(4-chlorobenzoyl) melatonin is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies Biochem. Pharmacol. 75 2008 484 493
72. A.J. Liedtke, A.O. Adeniji, M. Chen, M.C. Byrns, Y. Jin, D.W. Christianson, L.J. Marnett, and T.M. Penning Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer J. Med. Chem. 56 2013 2429 2446
73. M. Chen, A.O. Adeniji, B.M. Twenter, J.D. Winkler, D.W. Christianson, and T.M. Penning Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer Bioorg. Med. Chem. Lett. 22 2012 3492 3497
74. M. Yepuru, Z. Wu, A. Kyulkarni, F. Yin, C.M. Barrett, J. Kim, M.S. Steiner, D.D. Miller, J.T. Dalton, and R. Narayanan Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth Clin. Cancer Res. 19 2013 5613 5625
75. A. Kikuchi, T. Furutani, H. Azami, K. Watanbe, T. Nimi, Y. Kamiyama, S. Kuromitsu, E. Bakin-Bey, M. Heeringa, T. Uoatas, and K. Enjo In vitro and in vivo characterization of ASP9521: a novel selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5; AKR1C3) Invest. New Drugs 32 2014 860 870
76. Y. Loriot, K. Fizazi, R.J. Jones, Brand, J. Van den, R.L. Molife, A. Omlin, N.D. James, E. Baskin-Bey, M. Heeringa, B. Baron, G.M. Holtkamp, T. Ouatas, and J.S. de Bono Safety, tolerability and anti-tumor activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study Invest. New Drugs 32 2014 995 1004
77. E.A. Mostaghel, S.R. Plymate, and B. Montgomery Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit Clin. Cancer Res. 20 2014 791 798
78. M. Nakka, I.U. Agoulnik, and N.L. Weigel Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells Int. J. Biochem. Cell. Biol. 45 2013 763 772
79. M. Fankhauser, Y. Tan, G. Macintyre, I. Haviv, M.K.H. Hong, A. Nguyen, J.S. Pederson, A.J. Costello, C.M. Hovens, and N.M. Corcoran Canoncial androstenedione reduction is the predominat source of signaling androgens in hormone-refractory prostate cancer Clin. Cancer Res. 20 2014 5547 5557